Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Revenue (2021)

Atea Pharmaceuticals (AVIR) has 1 years of Revenue data on record, last reported at $192.2 million in Q4 2021.

  • For Q4 2021, Revenue changed N/A year-over-year to $192.2 million; the TTM value through Sep 2022 reached $192.2 million, up 20.73%, while the annual FY2021 figure was $351.4 million, 622.49% up from the prior year.
  • Revenue reached $192.2 million in Q4 2021 per AVIR's latest filing, up from $32.8 million in the prior quarter.
  • Across five years, Revenue topped out at $192.2 million in Q4 2021 and bottomed at $32.8 million in Q3 2021.